• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Role of rTMS in Poststroke Depression

The Role of rTMS in Poststroke Depression

January 7, 2022
Susan L. Siegfreid, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Susan L. Siegfreid, MD Dr. Siegfreid has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Hordacre B et al, J Neurol 2021;268(4):1474–1484

STUDY TYPE: Randomized controlled trial

Poststroke depression is common, disabling, and often treatment refractory. We know repetitive transcranial magnetic stimulation (rTMS) is effective for treatment-resistant depression. Might it offer a safe and effective treatment for poststroke depression? Two previous small randomized controlled trials of rTMS (using high-frequency [10 Hz] delivery of 1,000 pulses per session to the left dorsolateral prefrontal cortex for 10 sessions) demonstrated both safety and efficacy in poststroke depression (Gu SY and Chang MC, Brain Stimul 2017;10(2):270–274; Jorge RE et al, Biol Psychiatry 2004;55(4):398–405). Researchers in the current study hypothesized that delivery of a higher dose—3,000 pulses per session—would increase clinical benefit without compromising safety.

The study recruited 11 patients with moderate (baseline PHQ-9 score > 5) poststroke depression and no change in antidepressant medication for the prior six months. Most of the patients (n = 9) were male, ages 44–78 years, with predominantly right hemispheric strokes occurring one to 11 years prior to enrollment. Participants were randomized to either active (n = 6) or sham (n = 5) rTMS groups using an identical figure-8 coil. They received 10 treatment sessions, occurring over five weekdays for two consecutive weeks. The primary outcome measure for depression severity was the Beck Depression Inventory-II (BDI), which was assessed at baseline, immediately after treatment, and at one month follow-up.

From baseline to one-month follow-up, the BDI scores in the treatment group decreased significantly more than in the sham group, with an average change of 12 points (p = 0.04). Adverse effects were transient and comparable between the treatment and sham groups.

CHPR’S TAKE
This study was small and only followed moderately depressed patients for one month after treatment, but it provides additional evidence that higher-dose rTMS is a safe and effective treatment option for poststroke depression in patients who do not fully respond to antidepressant medication.
Hospital Psychiatry
KEYWORDS depression post-stroke-depression rtms stroke tms transcranial-magnetic-stimulation treatment
    Susan L. Siegfreid, MD

    Dose-Dependent Mortality Risk for Second-Generation Antipsychotics in Young Adults

    More from this author
    www.thecarlatreport.com
    Issue Date: January 7, 2022
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Testifying, CHPR, January/February/March 2022
    A Primer for Psychiatrists on Court Hearings
    Borderline Personality Disorder in the ED
    Tarasoff: Making Sense of the Duty to Warn or Protect
    Principles of Verbal De-Escalation
    Minimizing PTSD From Workplace Trauma
    The Role of rTMS in Poststroke Depression
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.